Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell save search
SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas
Published: 2023-10-30 (Crawled : 13:00) - globenewswire.com
SLS | $1.615 4.87% 4.64% 2M
|
Health Technology
|
| O: 6.88%
H: 19.0%
C: 16.0%
sls009 fda t-cell life treatment designation sciences lymphomas
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
Published: 2023-10-26 (Crawled : 13:00) - globenewswire.com
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 10.19%
H: 21.97%
C: -18.5%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: -0.53%
H: 2.93%
C: -4.26%
mb-109 fda mb-101 cell treatment application car-t glioblastoma
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform
Published: 2023-10-26 (Crawled : 11:00) - globenewswire.com
MRNA | News S | $107.87 3.26% 3.16% 2.4M
|
Health Technology
|
| O: -0.04%
H: 0.64%
C: -0.98%
GBIO | News | $3.27 16.37% 14.07% 210K
|
Health Technology
|
| O: 1.28%
H: 2.11%
C: 0.85%
cell platform
Regen BioPharma, Inc. Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program
Published: 2023-10-25 (Crawled : 13:30) - prnewswire.com
RGBP | $0.7 5.69% 1.5K
|
Manufacturing
|
| O: 4.29%
H: 10.0%
C: 10.0%
cell car-t program therapy
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
Published: 2023-10-23 (Crawled : 18:00) - biospace.com/
ADAP | $1.12 10.89% 9.82% 1.1M
|
Health Technology
|
| O: 6.19%
H: 3.33%
C: 0.05%
t-cell update trial therapy
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
Published: 2023-10-23 (Crawled : 15:30) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -0.48%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
BNTX | News | $88.53 0.59% 0.59% 360K
|
Health Technology
|
| O: -2.24%
H: 7.12%
C: 4.11%
bnt211 candidate congress tumors positive update cell car-t therapy
Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
Published: 2023-10-21 (Crawled : 16:20) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
| Email alert
Add to watchlist
hpn328 congress cell trial therapeutics response
EvolveImmune Therapeutics to Present New Preclinical and Translational Data Highlighting Precision Medicine Potential of its Novel Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Published: 2023-10-18 (Crawled : 15:00) - biospace.com/
IMUN | $0.093 214.52% 1.8K
|
Manufacturing
| Email alert
Add to watchlist
cancer cell preclinical immunotherapy meeting therapeutics potential platform
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Published: 2023-10-18 (Crawled : 12:00) - globenewswire.com
CRBU | $3.98 -0.25% -0.25% 930K
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: -5.35%
cb-012 fda cell treatment clearance application car-t leukemia therapy
Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1
Published: 2023-10-16 (Crawled : 13:00) - globenewswire.com
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: -4.43%
H: 3.6%
C: 3.6%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 0.34%
H: 4.12%
C: -4.81%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -1.07%
H: 2.0%
C: 1.82%
biotech worldwide hope cell treatment city agreement therapy living
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress
Published: 2023-10-13 (Crawled : 12:30) - prnewswire.com
NKTR | News | $1.415 4.04% 3.89% 1.1M
|
Health Technology
|
| O: 3.39%
H: 1.63%
C: -0.37%
t-cell congress presentation
ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibits T Cell Proliferation, Reduces Inflammatory Cytokines, and Down Modulates BTLA Expression on Circulating T and B Cells: Results from a First-in-Human Phase 1 Study
Published: 2023-10-13 (Crawled : 07:00) - anaptysbio.com
ANAB | $19.21 -2.29% -2.34% 390K
|
Health Technology
|
| O: -0.32%
H: 2.22%
C: 1.78%
anb032 agonist cell results study
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma
Published: 2023-10-12 (Crawled : 12:00) - globenewswire.com
INAB | $1.035 3.51% 3.39% 280K
|
|
| O: 1.0%
H: 0.0%
C: -5.94%
inb-100 inb-400 cell treatment trial potential therapy glioblastoma
SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas
Published: 2023-10-11 (Crawled : 13:00) - globenewswire.com
SLS | $1.615 4.87% 4.64% 2M
|
Health Technology
|
| O: -0.7%
H: 7.8%
C: -14.89%
sls009 t-cell lymphomas trial
GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)
Published: 2023-10-10 (Crawled : 12:30) - biospace.com/
SLS | $1.615 4.87% 4.64% 2M
|
Health Technology
|
| O: 0.0%
H: 10.48%
C: -0.7%
gfh009 t-cell lymphomas trial
Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
Published: 2023-10-09 (Crawled : 20:00) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: -2.12%
H: 11.81%
C: 1.86%
hpn328 congress cell trial therapeutics response
Cell Therapy Market to grow by USD 31.04 billion from 2022 to 2027 | Proven effectiveness of CAR T-cell therapy boosts the market - Technavio
Published: 2023-10-04 (Crawled : 18:00) - prnewswire.com
LSTA | $2.67 -2.08% 13K
|
Manufacturing
|
| O: 3.86%
H: 0.93%
C: -2.33%
ALPMY | News | $9.53 -1.11% 690K
|
Manufacturing
|
| O: 0.59%
H: 0.29%
C: 0.22%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -1.21%
H: 1.3%
C: 1.16%
BCLI A | $0.531 -1.69% -1.71% 170K
|
Health Technology
|
| O: -0.37%
H: 10.94%
C: -4.38%
t-cell cell therapy market
Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy
Published: 2023-10-04 (Crawled : 13:00) - biospace.com/
ATNM | $6.96 -2.93% -1.14% 190K
|
Health Technology
|
| O: 0.87%
H: 2.41%
C: -0.69%
cd45 cell extension grant car-t therapy
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
Published: 2023-10-02 (Crawled : 14:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -1.77%
H: 0.0%
C: 0.0%
NKTR | News | $1.415 4.04% 3.89% 1.1M
|
Health Technology
|
| O: -2.01%
H: 4.52%
C: -2.35%
t-cell congress therapeutics therapy
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Published: 2023-09-27 (Crawled : 20:00) - globenewswire.com
CLLS | News | $2.535 -3.98% -4.14% 47K
|
Health Technology
|
| O: -1.25%
H: 2.22%
C: 0.0%
pre-clinical breast cancer immunotherapy meeting
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.